The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

GSK claims Moderna is marketing the products in violation of its intellectual property without licenses. In the lawsuits, GSK’s legal team said the company hopes to recover a “reasonable ...

GlaxoSmithKline (GSK) is a global biopharmaceutical company that focuses on the development and marketing of medicines, vaccines, and healthcare products, with a strong emphasis on innovation in ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

General Anesthesia Drugs MarketThe global general anesthesia drugs market, valued at USD 4,978.1 million in 2023, is poised for steady growth, with projections indicating a compound annual growth rate ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn ... reflecting strong performance of new products and the investment we've put ...